title: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
abstract: Virtually no progress has been made during more than 2 decades of clinical trials for multiple myeloma (MM) involving standard therapy (ST). Recent studies suggest that dose intensification requiring hematopoietic stem cell support results in higher complete response (CR) rates and extended disease control. "Total Therapy" (TT) consisting of noncross-resistant induction regimens, followed by a double autotransplant (AT) procedure, was administered to 123 untreated patients with symptomatic MM. Upon hematologic recovery, interferon (IFN) maintenance (3 million units [MU]/m2 subcutaneously thrice weekly) was given until disease recurrence/progression. Results were compared with the outcome of untreated patients receiving ST according to Southwest Oncology Group (SWOG) trials. One hundred sixteen pair mates were selected from both TT and among 1,123 patients to match for the major prognostic features. TT induced CR in 40% of all 123 patients (intent-to-treat). By 12 months, 7% had died, including 4% from treatment-related complications. With a median follow-up of 31 months, median durations of event-free survival (EFS) and overall survival (OS) are 49 and 62+ months, respectively. Abnormalities of chromosomes 11q and 13 were associated with inferior outcome, whereas CR within 6 months after induction was a favorable prognostic feature for both EFS and OS. In comparison to ST, TT induced higher PR rates (85% v 52%, P < .0001) (CR rates not available on SWOG trials) and extended EFS (49 v 22 months, P = .0001) and OS (62+ v 48 months, P = .01). Compared to ST, dose intensification with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but also significantly extending EFS and OS in previously untreated patients with MM.
authors.affiliation: Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock 72205, USA.
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: D H
authors.initials: DH
authors.lastname: Vesole
authors.forename: S
authors.initials: S
authors.lastname: Naucke
authors.forename: B
authors.initials: B
authors.lastname: Cheson
authors.forename: S
authors.initials: S
authors.lastname: Mattox
authors.forename: D
authors.initials: D
authors.lastname: Bracy
authors.forename: S
authors.initials: S
authors.lastname: Salmon
authors.forename: J
authors.initials: J
authors.lastname: Jacobson
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: G
authors.initials: G
authors.lastname: Tricot
mesh_terms: D000368:Aged; D000380:Agranulocytosis / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery*; D011379:Prognosis; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000209:etiology; D014182:Transplantation, Autologous / Q000009:adverse effects